Short‐Term Efficacy and Safety of Extended‐Release Fluvastatin in a Large Cohort of Elderly Patients
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The efficacy and safety of lipid‐lowering agents in elderly individuals have not been extensively assessed. This population generally takes more drugs concurrently than middle‐aged patients, and are therefore at higher risk of drug‐drug interactions. This large‐scale, randomized, double‐blind, placebo‐controlled study investigated the efficacy and safety of extended‐release (XL) fluvastatin 80 mg once daily for up to 1 year in elderly patients with primary hypercholesterolemia. A total of 1229 patients (mean age, 75.5 years) were randomized. After 2 months of treatment, fluvastatin XL 80 mg significantly decreased plasma lipid levels from baseline compared with placebo; fluvastatin reduced total cholesterol by 25% compared with a decrease of 2.5% in the placebo group, low‐density lipoprotein cholesterol was −33% vs. −2.5%, respectively, and triglycerides were −13.3% vs. 2.9%, respectively (p<0.00001). The safety profile of fluvastatin XL was similar to that of placebo. Fluvastatin XL 80 mg once daily was well tolerated and effectively managed plasma lipid profiles in a large cohort of elderly patients. These findings are consistent with data obtained previously in younger recipients of fluvastatin XL 80 mg, and reinforce the safety of fluvastatin in a population at high risk of drug‐drug interactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lewis, S. J., Moye, L. A., Sacks, F. M., Johnstone, D. E., Timmis, G., Mitchell, J., Limacher, M., Kell, S., Glasser, S. P., Grant, J., et al. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-9-199811010-00002 · Cited by 427
Cited by
A systematic review and economic evaluation of statins for the prevention of coronary events
Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., & Payne, N. (2007) · Health Technology Assessment · doi:10.3310/hta11140 · Cited by 556
Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials
Kashani, A., Phillips, C. O., Foody, J. M., Wang, Y., Mangalmurti, S., Ko, D. T., & Krumholz, H. M. (2006) · Circulation · doi:10.1161/circulationaha.106.624890 · Cited by 474
Prevalence of statin intolerance: a meta-analysis
Bytyçi, I., Penson, P. E., Mikhailidis, D. P., Wong, N. D., Hernandez, A. V., Sahebkar, A., Thompson, P. D., Mazidi, M., Rysz, J., Pella, D., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac015 · Cited by 481
Charytan, D., & Kuntz, R. E. (2006) · Kidney International · doi:10.1038/sj.ki.5001934 · Cited by 271
Benefits of Statins in Elderly Subjects Without Established Cardiovascular Disease
Savarese, G., Gotto, A. M., Paolillo, S., D'Amore, C., Losco, T., Musella, F., Scala, O., Marciano, C., Ruggiero, D., Marsico, F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.069 · Cited by 219
Metadata
- Authors
- Bruckert, E., Lièvre, M., Giral, P., Crepaldi, G., Masana, L., Vrolix, M., Leitersdorf, E., & Dejager, S.
- Venue
- The American Journal of Geriatric Cardiology
- Publisher
- Wiley
- Published
- 2003-07
- Volume
- 12
- Issue
- 4
- Pages
- 225-231
- ISSN
- 1076-7460 (ISSN-L)
- 1751-715X
- OpenAlex
- W2041681707
- Cited by
- 35
- References
- 1
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Short‐Term Efficacy and Safety of Extended‐Release Fluvastatin in a Large Cohort of Elderly Patients. https://app.cochat.ai/papers/10.1111/j.1076-7460.2003.02000.x
- The paper
- Bruckert, E., Lièvre, M., Giral, P., Crepaldi, G., Masana, L., Vrolix, M., Leitersdorf, E., & Dejager, S. (2003). Short‐Term Efficacy and Safety of Extended‐Release Fluvastatin in a Large Cohort of Elderly Patients. The American Journal of Geriatric Cardiology. https://doi.org/10.1111/j.1076-7460.2003.02000.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.